Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

Hematol Oncol. 2023 Aug;41(3):567-570. doi: 10.1002/hon.3080. Epub 2022 Oct 10.
No abstract available

Publication types

  • Multicenter Study
  • Letter

MeSH terms

  • Cyclophosphamide
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Mutation
  • Prognosis
  • Treatment Outcome

Substances

  • Cyclophosphamide